Vaksin Terapeutik yang Menargetkan Onkoprotein E6 dan E7 pada Kanker Serviks

Maya Savira


Cervical cancer is caused by persistent high-risk type of human papillomavirus (HPV) infection. especially types 16 and 18. The choice of cervical cancer therapy is associated with many side effects, tumor drug resistance, and high costs. A more efficient, safe and effective cervical cancer therapy is needed, such as therapeutic vaccine which targets host factors related to E6 and E7 of HPV oncoprotein. The oncoprotein E6 targets and inhibits p53, whereas E7 inhibits pRb. Therapeutic vaccines can be used to treat cervical cancer in all stage. Currently, this therapeutic vaccine is under investigation in phase I/II/III clinical trials.


Evriati PR, Yasmon A. Patogenesis human papillomavirus (HPV) pada kanker serviks. jurnal biotek medisiana Indonesia. 2019; 8(1).p.23-32. Available from :

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, and Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018; 68.p.394-424. Available from:

Marlina M, Aldi Y, Putra AE, Sopianti DS, Hari DG, Arfiandi A, et al. Identification of the type of human papillomavirus (HPV) in patients with cervical cancer. Jurnal Sains Farmasi& Klinis. 2016; 3(1).p.54-63. Available from :

Burmeister CA, Khan SF, Schafer G, Mbatani N, Adams T, Moodley J, et al. Cervical Cancer Therapies: Current Challenges and Future Perspectives. ELSEVIER 2022;13.p.1-14. Available from:

Gultom DA. Patogenitas human papillomavirus (HPV) dalam onkogenesis kanker serviks dan pengembangan vaksin pencegahannya. 2021; 8(2).p.2579-7557. Available from:

Shirng J, Daniel F, Murray MW, Iden M, Zimmermann MT, and Flister MJ. Genetic variations in human papillomavirus and cervical cancer outcomes. Int. J. Cancer. 2019; 144(9): p.2206 2214. Available from:

1.7. Nicole SLYT, Yoshiaki I, and Sudhakar J. High-risk human papillomaviral oncogenes E6 and E7 target key cellular pathways to achieve oncogenesis. Int. J. Mol. Sci. 2018; 19(6),1706. p. 1-27. Available from:

McBride AA, Warburton A. The role of integration in oncogenic progression of HPV-associated. cancers. PLOS Pathogens. 2017. p.1-7. Available from:

Pal A. Kundu R. Human Papillomavirus E6 dan E7: The cervical cancer hallmarks and target for therapy. Frontiers in Microbiology. 2020; 10(3116).p.1-15. Available from:

Garbuglia AR, Lapa D, Sias C, Capobianchi MR, and Porto PD. The use of both therapeutic and prophylactic vaccine in the theraphy of papillomavirus disease. Frontiers in immunology. 2020; 11(188): 1-14. Available from:

Chabeda A, Yanez RJR, Lamprecht R, Meyers AE, Rybicki EP and Hitzeroth II. Therapeutic vaccines for high risk HPV-associated diseases. Papillomavirus Res.2018; 5: 46-58. Available from :

Boilesen DR, Nielsen KN, Holst PJ. Novel antigenic targets of HPV therapeutic vaccines. Vaccines Jounal. 2021; 9.1262: p.1-22. Available from :

Yang A, Jeang J, Cheng K, Cheng T, Yang B, Wu TC, et al. Current state in the development of candidate therapeutic HPV vaccines. Expert Rev. Expert Review of Vaccines. 2016: 15(8). Available from :

Hung CF, Ma B, Monie A, Tsen SW, and Wu TC. Therapeutic human papillomavirus vaccines: Current clinical trials and future directions Expert Opinion on Biological Therapy. 2008; 8(4): 421-39. Available from:

Hasan Y, Furtado L, Tergas A, Lec N, Brooks R, McCall A, et al. A Phase 1 trial assessing the safety and tolerability of a therapeutic DNA vaccination against HPV I6 and HPV18 E6/E7 oncogenes after chemoradiation for cervical cancer. Int. J. Radiat Oncol. Biol. Phys. 2020; 107(3): 487-98. Available from:

Akhatova A, Chan CK, Azizan A, and Aimagambetova G. The efficacy of therapeutic DNA vaccines expressing the human papillomavirus E6 and E7 oncoproteins for treatment of cervica cancer systematic review. Vaccines Journal. 2022; 10(53): 1-12. Available from:


  • There are currently no refbacks.